Affiliation: NYU Langone Health, New York, NY PURPOSE: The medial sural artery perforator (MSAP) flap offers thin, pliable tissue with a relatively long pedicle. Compared to other thin fasciocutaneous flaps, its relatively low donor site morbidity makes the MSAP flap a valuable option for the reconstructive microsurgeon. The purpose of this study is to systematically evaluate the literature on use of MSAP flaps with regards to flap characteristics, indications, recipient site defects, and postoperative outcomes.
RESULTS:
Thirty-five studies encompassing 526 MSAP flaps were included for analysis. The most common reasons for surgery were oncologic (47.6%) and traumatic injuries (31.8%). The oral cavity was the most common recipient location (45.5%). Average flap dimensions were 6.0 ± 2.3cm by 9.8 ± 3.6cm with an average pedicle length of 10.1 ± 6.6cm. Meta-analysis revealed an overall complication rate of 14.3% (Q value=22.16, p=0.877, I 2 = -39.9 ). Use of chimeric MSAP flaps was associated with significantly higher rates of complications (OR=3.92, p=0.039, 95% CI 1.10-13.89). The majority of flap donor sites were closed primarily (68%) versus 32% that were covered with a split-thickness skin graft (STSG). A flap width greater than 5.75cm had an OR=5.3 (95% CI, 1.3-21.8; p=0.014) of having a donor site complication if closed primarily. Donor site complication rate was 1.9% (n=10) overall. Out of 247 MSAP flaps, 68% were closed primarily versus 32% covered with a split-thickness skin graft (STSG). Average dimensions for flaps whose donor site was closed with a STSG (8.0cm by 12.2cm) was significantly greater than those closed primarily (5.0cm by 8.9cm, p<0.0001). Among those that underwent primary closure, a flap width greater than 5.75cm had an OR=5.3 (95% CI, 1.3-21.8; p=0.014) of having a donor site complication. There was no significant difference in donor site complications based on patient gender or use of primary closure versus STSG.
CONCLUSION: This is the first systematic literature review and meta-analysis demonstrating the efficacy and safety of the MSAP flap. Our results emphasize the utility of the MSAP flap as a potential workhorse flap for various recipient sites requiring thin, pliable tissue and a relatively long pedicle. With a favorable donor site that can be closed primarily in a flap width of nearly 6cm, the potential benefits of this flap cannot be understated. BACKGROUND: Upwards of 75% of major limb amputees suffer from chronic pain, either isolated to the residual limb stump or perceived in the missing limb, known as phantom limb pain. At present time, there are no reliable and reproducible treatments for these chronic pain conditions. Targeted muscle reinnervation is a surgical procedure initially created to achieve improved prosthetic control by rerouting cut nerve endings to redundant motor nerves. As part of a military-civilian collaboration, TMR was incidentally discovered to ameliorate chronic pain and PSTM 2018 Abstract Supplement
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was thus proposed in this study as a potential preventative pain measure when performed concurrently at the time of amputation.
METHODS:
TMR was performed concurrently in 40 patients undergoing major limb amputation as a preemptive measure for symptomatic neuromas and phantom limb phenomena across four centers. Outcomes were assessed using the Patient-Reported Outcomes Measurement Information System (PROMIS) and a Numerical Rating Scale and were compared to a cross-section of 727 untreated amputee controls. One-way ANOVA followed by pairwise comparisons of means was conducted between cohorts.
RESULTS:
Patients undergoing TMR concurrently with major limb amputation had dramatic improvement in residual limb and phantom limb pain compared to untreated amputee controls across all measures. PROMIS score mean differences for phantom limb pain were 8.1 (CI 5.5-10.7) for Pain Intensity, 8.3 (CI 5.3-11.2) for Pain Behavior and 8.6 (CI 6.0-11.2) for Pain Interference, all p<0.001. Mean differences for residual limb pain were 8.4 (CI 5.4-11.3), 10.1 (CI 6.8-13.5), and 8.9 (CI 5.7-12.1) for PROMIS Pain Intensity, Behavior, and Interference, respectively (all p<.001). Numerical Rating Scale (NRS) data also revealed similar improvements in average residual limb pain (1.98 vs 3.89) and phantom limb pain (2.14 vs 3.96) for concurrent TMR amputees compared to the general amputee population.
CONCLUSION:
Preemptive Targeted Muscle Reinnervation at the time of limb loss should become standard of care for prevention of pathologic phantom and residual limb pain in amputees.
